EHC
Encompass Health Corporation
EHC has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over EHC overall, supported by stronger fundamentals and stronger modeled upside.
EHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
EHC's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
EHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $112 | -20% |
| Forward | 21x | $141 | — |
| Fair | 22x | $139 | -1.3% |
| Current | 22x | $141 | — |
| Expensive | 24x | $157 | +11% |
Historical ranges are pointers, not guarantees.
EHC's PE is in its fair range at 22x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over EHC in the historical PE scenario, which offers more potential upside but is not a forecast.
EHC Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for EHC, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over EHC on the outlook, with more favorable valuation expectations.
EHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.72 | +4.9% |
| Q3 2026 | $6.40 | +21% |
| Q2 2026 | $6.14 | +20% |
| Q1 2026 | $5.99 | +24% |
| Q4 2025 | $5.54 | +24% |
| Q3 2025 | $5.29 | +28% |
| Q2 2025 | $5.11 | +30% |
| Q1 2025 | $4.84 | +31% |
| Q4 2024 | $4.46 | +29% |
EHC has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
EHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +8.9% |
| Q2 2026 | $1.6B | +9.6% |
| Q1 2026 | $1.6B | +9% |
| Q4 2025 | $1.5B | +9.9% |
| Q3 2025 | $1.5B | +9.4% |
| Q2 2025 | $1.5B | +12% |
| Q1 2025 | $1.5B | +11% |
| Q4 2024 | $1.4B | +13% |
EHC's revenue has grown year over year for 13 quarters in a row: $1.6B last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +1.4 points |
| Q2 2026 | 18% | +0.3 points |
| Q1 2026 | 19% | +0.7 points |
| Q4 2025 | 18% | +1.8 points |
| Q3 2025 | 16% | +1 points |
| Q2 2025 | 18% | +1.2 points |
| Q1 2025 | 18% | +2.6 points |
| Q4 2024 | 17% | +1.3 points |
EHC has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over EHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
EHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.5M | +52% |
| Q2 2026 | $62.3M | -45% |
| Q1 2026 | $150.7M | +20% |
| Q4 2025 | $116.7M | +46% |
| Q3 2025 | $83.7M | -30% |
| Q2 2025 | $113.3M | +87% |
| Q1 2025 | $125.5M | +26% |
| Q4 2024 | $80.1M | +$101.7M |
EHC generated $457M in free cash flow over the past year, up 14% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
EHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -300K shares |
| 1 year | -2.5% | -2.6M shares |
| 3 years | -1.7% | -1.7M shares |
| 5 years | -0.5% | -500K shares |
| Available history | +0.3% | +300K shares |
EHC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $57.9M |
| Q2 2026 | $74.2M |
| Q1 2026 | $71.6M |
| Q4 2025 | $76.3M |
| Q3 2025 | $24.9M |
| Q2 2025 | $24.7M |
| Q1 2025 | $32.1M |
| Q4 2024 | $7.5M |
EHC spent $280M buying back its own shares over the past year, about three times what it spent the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
EHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.8x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 2.1x | Moderate |
EHC's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over EHC on leverage, with a lower net debt burden relative to earnings.
EHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.7 | Overbought |
| Stochastic | 88.7 | Overbought |
EHC's weekly RSI is 73 (overbought) and its Stochastic is 89 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
EHC PE vs Healthcare Sector
| Metric | EHC | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 15% below |
| PE % | 53 | 29 | 24 pts above |
EHC is trading at 22x earnings, a 15% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over EHC on valuation relative to its sector.
EHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.1 | 9.1% above |
| 20 week MA | $122.0 | 15% above |
| 50 week MA | $111.1 | 27% above |
| 100 week MA | $111.2 | 27% above |
| 200 week MA | $93.1 | 51% above |
EHC is in an uptrend: it's above all five of its weekly moving averages, and 51% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
EHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $55.5 | $65.7 | +19% |
| 2021 | $65.7 | $51.0 | -22% |
| 2022 | $51.0 | $59.3 | +16% |
| 2023 | $59.3 | $66.7 | +13% |
| 2024 | $66.7 | $93.6 | +40% |
| 2025 | $93.6 | $107.5 | +15% |
| 2026 YTD | $107.5 | $140.8 | +31% |
EHC has finished higher in five of the last six years. It's up 31% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over EHC on returns for 2026, with the stronger performance.